204 related articles for article (PubMed ID: 37438818)
1. Host obesity alters the ovarian tumor immune microenvironment and impacts response to standard of care chemotherapy.
Liu Y; Yang J; Hilliard TS; Wang Z; Johnson J; Wang W; Harper EI; Ott C; O'Brien C; Campbell L; Crowley B; Grisoli S; Stavrou NM; Juncker-Jensen A; Stack MS
J Exp Clin Cancer Res; 2023 Jul; 42(1):165. PubMed ID: 37438818
[TBL] [Abstract][Full Text] [Related]
2. Obesity modulates the cellular and molecular microenvironment in the peritoneal cavity: implication for ovarian cancer risk.
Shea AA; Heffron CL; Grieco JP; Roberts PC; Schmelz EM
Front Immunol; 2023; 14():1323399. PubMed ID: 38264656
[TBL] [Abstract][Full Text] [Related]
3. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
[TBL] [Abstract][Full Text] [Related]
4. High-fat diet and obesity are associated with differential angiogenic gene expression in epithelial ovarian cancer.
Baumann KE; Siamakpour-Reihani S; Dottino J; Dai Y; Bentley R; Jiang C; Zhang D; Sibley AB; Zhou C; Berchuck A; Owzar K; Bae-Jump V; Secord AA
Gynecol Oncol; 2023 Dec; 179():97-105. PubMed ID: 37956617
[TBL] [Abstract][Full Text] [Related]
5. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
Bandera EV; Lee VS; Rodriguez-Rodriguez L; Powell CB; Kushi LH
JAMA Oncol; 2015 Sep; 1(6):737-45. PubMed ID: 26181758
[TBL] [Abstract][Full Text] [Related]
6. Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer.
Glass EB; Hoover AA; Bullock KK; Madden MZ; Reinfeld BI; Harris W; Parker D; Hufnagel DH; Crispens MA; Khabele D; Rathmell WK; Rathmell JC; Wilson AJ; Giorgio TD; Yull FE
BMC Cancer; 2022 May; 22(1):497. PubMed ID: 35513776
[TBL] [Abstract][Full Text] [Related]
7. Obesity increases tumor aggressiveness in a genetically engineered mouse model of serous ovarian cancer.
Makowski L; Zhou C; Zhong Y; Kuan PF; Fan C; Sampey BP; Difurio M; Bae-Jump VL
Gynecol Oncol; 2014 Apr; 133(1):90-7. PubMed ID: 24680597
[TBL] [Abstract][Full Text] [Related]
8. Pro-inflammatory M1 macrophage enhances metastatic potential of ovarian cancer cells through NF-κB activation.
Cho U; Kim B; Kim S; Han Y; Song YS
Mol Carcinog; 2018 Feb; 57(2):235-242. PubMed ID: 29024042
[TBL] [Abstract][Full Text] [Related]
9. Obesity Contributes to Ovarian Cancer Metastatic Success through Increased Lipogenesis, Enhanced Vascularity, and Decreased Infiltration of M1 Macrophages.
Liu Y; Metzinger MN; Lewellen KA; Cripps SN; Carey KD; Harper EI; Shi Z; Tarwater L; Grisoli A; Lee E; Slusarz A; Yang J; Loughran EA; Conley K; Johnson JJ; Klymenko Y; Bruney L; Liang Z; Dovichi NJ; Cheatham B; Leevy WM; Stack MS
Cancer Res; 2015 Dec; 75(23):5046-57. PubMed ID: 26573796
[TBL] [Abstract][Full Text] [Related]
10. Impact of obesity on secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer.
Tran AQ; Cohen JG; Li AJ
Gynecol Oncol; 2015 Aug; 138(2):263-6. PubMed ID: 26037901
[TBL] [Abstract][Full Text] [Related]
11. Impact of obesity on breast cancer recurrence and minimal residual disease.
Ecker BL; Lee JY; Sterner CJ; Solomon AC; Pant DK; Shen F; Peraza J; Vaught L; Mahendra S; Belka GK; Pan TC; Schmitz KH; Chodosh LA
Breast Cancer Res; 2019 Mar; 21(1):41. PubMed ID: 30867005
[TBL] [Abstract][Full Text] [Related]
12. Downregulated Dual-Specificity Protein Phosphatase 1 in Ovarian Carcinoma: A Comprehensive Study With Multiple Methods.
Liang ZQ; He RQ; Luo JY; Huang ZG; Li J; Zhong LY; Chen JH; Huang SN; Shi L; Wei KL; Zeng JH; Zeng JJ; Chen G
Pathol Oncol Res; 2022; 28():1610404. PubMed ID: 35911442
[No Abstract] [Full Text] [Related]
13. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.
Marchion DC; Bicaku E; Xiong Y; Bou Zgheib N; Al Sawah E; Stickles XB; Judson PL; Lopez AS; Cubitt CL; Gonzalez-Bosquet J; Wenham RM; Apte SM; Berglund A; Lancaster JM
Oncol Rep; 2013 May; 29(5):2011-8. PubMed ID: 23467907
[TBL] [Abstract][Full Text] [Related]
14. Response to immune checkpoint blockade improved in pre-clinical model of breast cancer after bariatric surgery.
Sipe LM; Chaib M; Korba EB; Jo H; Lovely MC; Counts BR; Tanveer U; Holt JR; Clements JC; John NA; Daria D; Marion TN; Bohm MS; Sekhri R; Pingili AK; Teng B; Carson JA; Hayes DN; Davis MJ; Cook KL; Pierre JF; Makowski L
Elife; 2022 Jul; 11():. PubMed ID: 35775614
[TBL] [Abstract][Full Text] [Related]
15. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
Dasari VR; Carey DJ; Gogoi R
BMC Cancer; 2020 Apr; 20(1):273. PubMed ID: 32245422
[TBL] [Abstract][Full Text] [Related]
16. Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.
Shakfa N; Li D; Conseil G; Lightbody ED; Wilson-Sanchez J; Hamade A; Chenard S; Jawa NA; Laight BJ; Afriyie-Asante A; Tyryshkin K; Koebel M; Koti M
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37015760
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
Cibula D; Rob L; Mallmann P; Knapp P; Klat J; Chovanec J; Minar L; Melichar B; Hein A; Kieszko D; Pluta M; Spacek J; Bartos P; Wimberger P; Madry R; Markowska J; Streb J; Valha P; Hassan HIB; Pecen L; Galluzzi L; Fucikova J; Hrnciarova T; Hraska M; Bartunkova J; Spisek R
Gynecol Oncol; 2021 Sep; 162(3):652-660. PubMed ID: 34294416
[TBL] [Abstract][Full Text] [Related]
18. Plasma Gelsolin Confers Chemoresistance in Ovarian Cancer by Resetting the Relative Abundance and Function of Macrophage Subtypes.
Asare-Werehene M; Tsuyoshi H; Zhang H; Salehi R; Chang CY; Carmona E; Librach CL; Mes-Masson AM; Chang CC; Burger D; Yoshida Y; Tsang BK
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205790
[TBL] [Abstract][Full Text] [Related]
19. DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer.
Travers M; Brown SM; Dunworth M; Holbert CE; Wiehagen KR; Bachman KE; Foley JR; Stone ML; Baylin SB; Casero RA; Zahnow CA
Cancer Res; 2019 Jul; 79(13):3445-3454. PubMed ID: 31088836
[TBL] [Abstract][Full Text] [Related]
20. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Clamp AR; James EC; McNeish IA; Dean A; Kim JW; O'Donnell DM; Hook J; Coyle C; Blagden S; Brenton JD; Naik R; Perren T; Sundar S; Cook AD; Gopalakrishnan GS; Gabra H; Lord R; Dark G; Earl HM; Hall M; Banerjee S; Glasspool RM; Jones R; Williams S; Swart AM; Stenning S; Parmar M; Kaplan R; Ledermann JA
Lancet; 2019 Dec; 394(10214):2084-2095. PubMed ID: 31791688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
